CTLA4 and cancer: Various types of cancers evade T-cell responses and host immunity via adaptive negative regulators or co-inhibitory (checkpoint) receptors, such as programmed cell death-1 (PD-1) and their respective ligands, programmed cell death-ligand 1 (PD-L1 or B7-H1), programmed cell death-ligand 2 (PD-L2), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and CD80 (B7.1) or CD86 (B7.2) [1,2].